Clinical Trial Update: Assessment of Chikungunya Virus Seroprevalence Before VLA1553 Vaccination in the Municipalities Selected for Participation in the VLA1553 Pilot Vaccination Strategy in Brazil

View source ↗

Summary

A Valneva-sponsored Brazil study is assessing baseline chikungunya virus seroprevalence in municipalities selected for the VLA1553 pilot vaccination before vacc…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chikungunya

Drugs mentioned

• VLA1553

Snippet

Sponsor: Valneva Austria GmbH | Conditions: Chikungunya Virus Infection | Status: ACTIVE_NOT_RECRUITING